Business

Biosimilar Business Roundup: October 2020

November 2nd 2020

By Skylar Jeremias

Companies continued to prove in October that rare regulatory approvals and a pandemic have not stopped them from moving forward with plans to further products and search for ways to save money.

SomaLogic Inks Proteomics Deal With FDA for Biomarker Development

October 30th 2020

By Tony Hagen

A collaboration with the FDA could lead to new forms of pharmacodymamic measurement that improve speed and efficiency of biosimilar development and approval.

Mvasi, Kanjinti Add Heft to Amgen's Third-Quarter Sales

October 29th 2020

By Tony Hagen

Amgen said its sales results for Mvasi (bevacizumab) and Kanjinti (trastuzumab) give it confidence that the US market for biosimilars is more viable than generally perceived.

Part 1: Chad Pettit on Amgen’s Assessment of the US Biosimilar Marketplace

October 27th 2020

Chad Pettit, MBA, executive director of marketing and team leader for global biosimilar launches at Amgen, discussed Amgen’s recent report on the state of the US biosimilars marketplace.

Pfizer's Biosimilar Revenues Soar 80%

October 27th 2020

By Tony Hagen

The strong growth of biosimilars Pfizer recently launched in the United States are part of the success story, although reference etanercept (Enbrel) sales have seen major erosion.

Alvotech Locks In $65 Million for Biosimilar Development

October 27th 2020

By Tony Hagen

With a sizeable round of fresh capital, Alvotech hopes to bring monoclonal antibodies and fusion proteins through the development pipeline.

Biogen, Samsung Report Third-Quarter Biosimilar Results

October 21st 2020

By Tony Hagen

Earnings fell overall for Biogen, although biosimilar revenues continued an upward climb.

Avalere: Step Therapy May Exacerbate Patient, Payer Costs

October 19th 2020

By Tony Hagen

An Avalere analysis suggests costs are more moderate and lower under a no–step therapy scenario for patients with Crohn disease.

Roche Earnings Hit by Biosimilar Competition, COVID-19

October 16th 2020

By Tony Hagen

Roche attributes a $3.83 billion reduction in sales to biosimilar competition.

Revance Reports Positive Findings for Potential Botox Competitor

October 15th 2020

By Tony Hagen

DaxibotulinumtoxinA met all end points in a study demonstrating longer duration of action, safety, and tolerability.